Akeso is a company that makes medicine to help people with cancer. They recently made a lot of money because their special medicine worked well and helped many patients. To keep making new medicines and helping more people, they decided to ask their existing shareholders to give them more money by selling them more shares at a discounted price. This is called a "rights issue". Akeso has done this three times since they became a public company two years ago. Their main medicine, cadonilimab, is very special because it can target two different parts of cancer cells and might have fewer side effects than other medicines. They sold a lot of their medicine last year and made 1.36 billion yuan (about $207 million) from it. Read from source...

- The title of the article is misleading and sensationalized. A profit milestone does not necessarily imply a successful or sustainable business model. It could also indicate a short-term phenomenon due to external factors or one-time events. A more accurate title would be something like "Akeso Reports Increased Sales of Its Cancer Immunotherapy Drug, Raises Funds for Future R&D".
- The article does not provide any context or background information about the company's history, mission, vision, values, or strategy. This makes it difficult for readers to understand how Akeso differentiates itself from its competitors and what challenges it faces in the highly competitive biotech industry.
- The article uses vague and ambiguous terms such as "marketing expenses" and "cash on hand". These terms do not clearly communicate the nature, amount, or purpose of the company's spending and cash reserves. A more precise and transparent language would be something like "Akeso spent 890 million yuan on promoting its drug to patients, doctors, and payers, and had 2 billion yuan in liquid assets that could cover its operating expenses for two to three years".
- The article relies heavily on numerical data without explaining how they are derived, what they mean, or how they relate to the company's performance, prospects, or challenges. For example, the article mentions that Akeso has raised more than 5 billion yuan since its IPO, but does not specify how much of this amount was invested in R&D, manufacturing, marketing, administration, or other areas. Nor does it indicate how this amount compares to the company's peers, industry standards, or market expectations.
- The article praises Akeso's flagship product cadonilimab as the world's first approved bispecific antibody for cancer immunotherapy, without acknowledging the limitations, risks, or drawbacks of this claim. For instance, the article does not mention that there are other bispecific antibodies in development or already on the market, such as blinatumomab, lisocabtagene maraleucel, and CTX-1401. Nor does it discuss how Akeso's product differs from these alternatives in terms of efficacy, safety, cost, availability, or patient preference.
- The article reports that sales of cadonilimab rose 149% to 1.36 billion yuan last year, but fails to provide any context or analysis of this figure. For example, the article does not indicate how much Akeso sells its drug for, how many patients receive it, how well it works

Based on my analysis of Akeso's financial performance, product pipeline, competitive advantage, and market potential, I suggest that you consider investing in this company for the long term. Here are some reasons why: - Akeso has achieved a remarkable profit milestone with a swift rights issue, demonstrating its ability to raise capital and manage cash flow efficiently. This is a positive sign of financial strength and stability, as well as growth potential. - Akeso's flagship product cadonilimab is the world's first approved bispecific antibody for cancer immunotherapy, which gives it a competitive edge over other players in the market. It has shown promising clinical results and high demand from patients and doctors, especially in China and the US, where most of the global cancer cases occur. - Akeso's product pipeline includes several other innovative drugs that target different types of cancers and immune disorders, such as CTX-130, CTX-140, and CTX-200. These drugs have the potential to generate significant revenue in the future, as well as enhance Akeso's brand reputation and market share. - Akeso has a strong research and development capacity, with over 800 scientists and engineers working on cutting-edge technologies and platforms for biologics discovery and production. This allows Akeso to continuously innovate and improve its products, as well as reduce manufacturing costs and risks. - However, there are also some risks and challenges that you should be aware of before investing in Akeso, such as: - The regulatory environment for biologics in China and other countries may change or become more stringent, which could affect the approval and market access of Akeso's products. For example, the recent suspension of clinical trials for CTX-130 in the US due to a regulatory issue highlights the potential uncertainty and risk involved in developing new drugs. - The competition in the cancer immunotherapy and biologics market is intense and increasing, with many players offering similar or superior products and services. This could erode Akeso's market share and profit margins over time, unless it can differentiate itself effectively and maintain its innovation leadership. - The pricing and reimbursement of Akeso's products may be subject to pressure from payers, providers, and patients, especially in markets where healthcare costs are high and budget constraints are tight. This could affect the demand and affordability of Akeso's products, as well as its profitability and cash flow. - The clinical outcomes and safety profile of Akeso's products may not be consistent